Finance

Lists
Why is RGNX down 3,72%?
Dive Deeper
RGNX:NASDAQ
Regenxbio Inc
7,77 USD
-3,72%
(-0,30) 1D
7,90 USD
+1,67% (+0,13)
After hours
Closed: 12-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RGNX...
Open
8,12 USD
High
8,29 USD
Low
7,74 USD
Mkt. cap
512,92 млн
Avg. vol.
1,40 млн
Volume
0,00
52-wk high
16,19 USD
52-wk low
5,46 USD
EPS
-3,79 USD
Beta
1,13
Shares outstanding
66,01 млн
No. of employees
371
Open
8,12 USD
High
8,29 USD
Low
7,74 USD
Mkt. cap
512,92 млн
Avg. vol.
1,40 млн
Volume
0,00
52-wk high
16,19 USD
52-wk low
5,46 USD
EPS
-3,79 USD
Beta
1,13
Shares outstanding
66,01 млн
No. of employees
371
News stories
From web sources and news partners
About Regenxbio Inc
CEO-
Employees371
Founded2008
HeadquartersРоквилл, Мэриленд, Америка Кошмо Штаттары
Sector-
Analyst ratings
Based on 10 analysts giving stock ratings to RGNX in the past 3 months
Strong buy
Buy
8
Hold
2
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for RGNX in the last 3 months.
Highest
Current 7,77 USD
42,00 USD (+440,54%)
Average
22,00 USD (+183,14%)
Lowest
10,00 USD (+28,70%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Initiated
22,00 USD
+183,1%
10/05/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
42,00 USD
+440,5%
09/25/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
21,00 USD
+170,3%
09/25/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
15,00 USD
+93,1%
09/21/2026
Paul Choi
Goldman Sachs
Hold
Maintained
10,00 USD
+28,7%
08/24/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
18,00 USD
+131,7%
08/24/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
29,00 USD
+273,2%
08/25/2026
Mara Goldstein
Clear Street
Buy
Maintained
32,00 USD
+311,8%
08/25/2026
William Maughan
Clear Street
Buy
Maintained
32,00 USD
+311,8%
08/24/2026
Luca Issi
RBC Capital
Buy
Maintained
19,00 USD
+144,5%
08/06/2026
Eliana Merle
Barclays
Hold
Downgraded
12,00 USD
+54,4%
08/07/2026
Mani Foroohar
Leerink Partners
Buy
Maintained
17,00 USD
+118,8%
05/15/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
52,00 USD
+569,2%
01/28/2026
Last report
2026-ж., 6-авг.
Fiscal period
Q2 2026
0,43 USD / -0,11 USD
+499,22%beat
Revenue / Est. (USD)
108,02 млн / 96,46 млн
+11,99%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
29,73 млн
30,34 млн
6,39 млн
108,02 млн
Cost of goods sold
61,83 млн
65,54 млн
68,41 млн
57,13 млн
Cost of revenue
61,83 млн
65,54 млн
68,41 млн
57,13 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
20,25 млн
22,38 млн
21,31 млн
21,62 млн
Operating expense
20,32 млн
22,43 млн
21,34 млн
21,63 млн
Total operating expenses
82,14 млн
87,97 млн
89,76 млн
78,76 млн
Operating income
-52,41 млн
-57,64 млн
-83,36 млн
29,26 млн
Other non operating income
-
-
-
-
EBT including unusual items
-61,94 млн
-67,15 млн
-90,05 млн
22,71 млн
EBT excluding unusual items
-61,94 млн
-67,15 млн
-90,05 млн
22,71 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
65,00 миң
54,00 миң
36,00 миң
12,00 миң
Net income
-61,94 млн
-67,15 млн
-90,05 млн
22,71 млн
Net profit margin
-208,32%
-221,34%
-1 408,59%
21,02%
Earnings per share
-1,20
-1,30
-1,72
0,43
Interest and investment income
3,64 млн
2,76 млн
2,02 млн
1,24 млн
Interest expense
-13,17 млн
-12,28 млн
-8,71 млн
-7,79 млн
Net interest expenses
-9,53 млн
-9,51 млн
-6,69 млн
-6,55 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-48,52 млн
-53,77 млн
-79,50 млн
33,02 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору